Biohaven (BHVN) EBIT (2021 - 2026)

Biohaven has disclosed EBIT across 6 years of filings, most recently posting -$130.4 million for Q1 2026.

• EBIT for Q1 2026 came in at -$130.4 million, up 41.13% year-over-year; the trailing twelve-month figure through Mar 2026 was -$654.2 million (up 29.15% YoY), and the FY2025 annual result was -$745.4 million, up 15.79% from the prior year.
• EBIT came in at -$130.4 million for Q1 2026 at Biohaven, up from -$142.7 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$67.6 million in Q3 2022 to a low of -$333.8 million in Q2 2024.
• The 5-year median for EBIT is -$169.4 million (2025), against an average of -$162.6 million.
• Across the five-year window, EBIT slumped 319.42% in 2022 and soared 52.31% in 2023, its largest moves.
• Biohaven's EBIT stood at -$213.4 million in 2022, then grew by 27.97% to -$153.7 million in 2023, then dropped by 23.56% to -$189.9 million in 2024, then rose by 24.85% to -$142.7 million in 2025, then grew by 8.62% to -$130.4 million in 2026.
• The last three EBIT figures came in at -$130.4 million (Q1 2026), -$142.7 million (Q4 2025), and -$169.4 million (Q3 2025), per Business Quant data.